The FDA has accepted Pharming Group’s supplemental new drug application for leniolisib in treating activated phosphoinositide 3-kinase delta syndrome, or APDS, in children aged 4 to 11 years, ...

AbbVie has launched its Produodopa therapy for Parkinson’s disease onto the market in the EU, becoming the first and only 24-hour levodopa-based subcutaneous ...